This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Intra-Cellular Therapies (ITCI) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Intra-Cellular (ITCI) delivered earnings and revenue surprises of 27.42% and 5.59%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Seer, Inc. (SEER) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Seer, Inc. (SEER) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Intra-Cellular Therapies (ITCI) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Intra-Cellular (ITCI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CRISPR Therapeutics AG (CRSP) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of 39.22% and 99.95%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights United Therapeutics, Intra-Cellular Therapies, Immunocore Holdings and Eli Lilly
by Zacks Equity Research
United Therapeutics, Intra-Cellular Therapies, Immunocore Holdings and Eli Lilly are part of the Zacks top Analyst Blog.
Has IntraCellular Therapies (ITCI) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Intra-Cellular Therapies (ITCI) and RxSight, Inc. (RXST) have performed compared to their sector so far this year.
3 Drug Stocks Most Wall Street Analysts Are Bullish About
by Ekta Bagri
Here we present three drug and biotech stocks, UTHR, ITCI and IMCR, which most analysts on Wall Street are optimistic about. These companies have upside potential for 2023 despite an uncertain macro environment.
Is DICE Therapeutics (DICE) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how DICE Therapeutics, Inc. (DICE) and Intra-Cellular Therapies (ITCI) have performed compared to their sector so far this year.
Can Intra-Cellular (ITCI) Climb 33% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 32.7% upside potential for Intra-Cellular (ITCI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Intra-Cellular's (ITCI) Caplyta Aids Growth, Overdependence a Woe
by Zacks Equity Research
Intra-Cellular Therapeutics (ITCI) currently has only one marketed product in its portfolio, Caplyta, approved for schizophrenia and bipolar disorders. The company is evaluating the candidate in several other indications.
Catalyst Pharmaceuticals (CPRX) to Post Q3 Earnings: What's Up?
by Zacks Equity Research
On Catalyst Pharmaceuticals' (CPRX) third-quarter earnings call, investors will likely focus on the sales performance of Firdapse approved for treating LEMS.
How Much Upside is Left in Intra-Cellular (ITCI)? Wall Street Analysts Think 33%
by Zacks Equity Research
The consensus price target hints at a 33.5% upside potential for Intra-Cellular (ITCI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Intra-Cellular (ITCI) Beat on Q3 Earnings and Sales Estimates
by Zacks Equity Research
Intra-Cellular Therapeutics (ITCI) posts a narrower-than-expected Q3 loss and sales also beat the mark. ITCI continues to advance its pipeline with developmental programs.
Intra-Cellular Therapies (ITCI) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Intra-Cellular (ITCI) delivered earnings and revenue surprises of 33.72% and 10.66%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Add Intra-Cellular Therapeutics (ITCI) Stock Now
by Zacks Equity Research
Intra-Cellular's (ITCI) product revenues are primarily driven by higher sales of its schizophrenia and bipolar disorder drug Caplyta. Caplyta is also being evaluated for other CNS indications.
Intra-Cellular Therapies (ITCI) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Intra-Cellular (ITCI) delivered earnings and revenue surprises of -16.46% and 12.93%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Is a Surprise Coming for Intra-Cellular (ITCI) This Earnings Season?
by Zacks Equity Research
Intra-Cellular (ITCI) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Arbutus Biopharma (ABUS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Arbutus (ABUS) delivered earnings and revenue surprises of 23.08% and 165.39%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Rhythm Pharmaceuticals, Inc. (RYTM) delivered earnings and revenue surprises of -12.66% and 58.13%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Intra-Cellular Therapies (ITCI) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Intra-Cellular (ITCI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Has HealthEquity (HQY) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how HealthEquity (HQY) and Intra-Cellular Therapies (ITCI) have performed compared to their sector so far this year.
Intra-Cellular Therapies (ITCI) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Intra-Cellular (ITCI) delivered earnings and revenue surprises of 16.13% and 5.16%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Atyr Pharma (LIFE) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Atyr Pharma (LIFE) delivered earnings and revenue surprises of -29.41% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Intra-Cellular Therapies (ITCI) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Intra-Cellular (ITCI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Intra-Cellular Therapies (ITCI) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Intra-Cellular (ITCI) delivered earnings and revenue surprises of 0% and 3.58%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?